Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploring the target scope of KEAP1 E3 ligase-based PROTACs
Guangyan Du, Jie Jiang, Nathaniel J. Henning, et al.
Cell chemical biology (2022) Vol. 29, Iss. 10, pp. 1470-1481.e31
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Advances and challenges in therapeutic targeting of NRF2
Albena T. Dinkova‐Kostova, Ian M. Copple
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 3, pp. 137-149
Open Access | Times Cited: 141
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer
Simone Adinolfi, Tommi Patinen, Ashik Jawahar Deen, et al.
Redox Biology (2023) Vol. 63, pp. 102726-102726
Open Access | Times Cited: 108
DCAF16-Based Covalent Handle for the Rational Design of Monovalent Degraders
Melissa Lim, Thang Do Cong, Lauren M. Orr, et al.
ACS Central Science (2024) Vol. 10, Iss. 7, pp. 1318-1331
Open Access | Times Cited: 22
Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1
Margot Meyers, Sabine Cismoski, Anoohya Panidapu, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 1, pp. 58-68
Open Access | Times Cited: 19
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Yilin Chen, Haoan Xue, Jianping Jin
Journal of Biological Chemistry (2024) Vol. 300, Iss. 5, pp. 107264-107264
Open Access | Times Cited: 17
Biophysical and Computational Approaches to Study Ternary Complexes: A ‘Cooperative Relationship’ to Rationalize Targeted Protein Degradation
Jake A. Ward, Carles Perez‐Lopez, Cristina Mayor‐Ruiz
ChemBioChem (2023) Vol. 24, Iss. 10
Open Access | Times Cited: 35
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology
Iacovos N. Michaelides, Gavin W. Collie
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3173-3194
Open Access | Times Cited: 26
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation
Seong Ho Hong, Anand Divakaran, Akane Osa, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 2, pp. 442-450
Open Access | Times Cited: 14
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Rahman Shah Zaib Saleem, Martin P. Schwalm, Stefan Knapp
Bioorganic & Medicinal Chemistry (2024) Vol. 105, pp. 117718-117718
Open Access | Times Cited: 9
Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation
Ying Wang, Tianzi Wei, Man Zhao, et al.
PLoS Biology (2024) Vol. 22, Iss. 5, pp. e3002550-e3002550
Open Access | Times Cited: 9
The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation
Tomasz Sobierajski, Joanna Małolepsza, Marta Pichlak, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104032-104032
Open Access | Times Cited: 9
Routes to molecular glue degrader discovery
Yanfen Liu, Jieyun Bai, Dong Li, et al.
Trends in Biochemical Sciences (2025)
Closed Access | Times Cited: 1
Antioxidants and Mechanistic Insights for Managing Dry Age-Related Macular Degeneration
Deepak Basyal, Sooyeun Lee, Hye Jin Kim
Antioxidants (2024) Vol. 13, Iss. 5, pp. 568-568
Open Access | Times Cited: 7
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Sandra Kuemper, Andrew G. Cairns, Kristian Birchall, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 6
Development of KEAP1-targeting PROTAC and its antioxidant properties: In vitro and in vivo
Se Yong Park, Raju Gurung, Jung Ho Hwang, et al.
Redox Biology (2023) Vol. 64, pp. 102783-102783
Open Access | Times Cited: 16
Advances in developing noncovalent small molecules targeting Keap1
Marilia Barreca, Yuting Qin, M Cadot, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 12, pp. 103800-103800
Open Access | Times Cited: 16
Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1
Qi Mingming, Hui Zhong, Zhaoyan Cheng, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 9184-9200
Closed Access | Times Cited: 15
Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation
Shareef Shaik, Prasanna Kumar Reddy Gayam, Manish Chaudhary, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107868-107868
Open Access | Times Cited: 5
Design and characterization of a heterobifunctional degrader of KEAP1
Hao Chen, Nghi Nguyen, Charlene M. Magtoto, et al.
Redox Biology (2022) Vol. 59, pp. 102552-102552
Open Access | Times Cited: 20
Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives
Yangguo Zhou, Qiong Zhang, Ziquan Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116270-116270
Closed Access | Times Cited: 4
Selective degradation of BRD9 by a DCAF16-recruiting targeted glue: mode of action elucidation and in vivo proof of concept
Scott J. Hughes, Wojciech J. Stec, Colin Davies, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Patenting perspective on Keap1 inhibitors (2019-2024)
Yue Luo, Wenlong Yang, Yuan Zhang, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Page 1 - Next Page

Scroll to top